Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01447927 · ClinicalTrials.gov registry record · Phase 2
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT01447927: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01447927 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01447927, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well metformin hydrochloride works in preventing esophageal cancer in patients with Barrett esophagus. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may keep esophageal cancer from forming.
Interventions
- OTHER placebo
- DRUG metformin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01447927
The ClinicalTrials.gov registry entry for NCT01447927 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01447927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01447927 about?
NCT01447927 is a clinical study titled "Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus". This randomized phase II trial studies how well metformin hydrochloride works in preventing esophageal cancer in patients with Barrett esophagus. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may keep esophageal cancer from forming.
What is the current status of trial NCT01447927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2012-06. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01447927?
The interventions under investigation include: placebo (OTHER), metformin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01447927?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.